Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study.

Mary E Westerman,Kelly K Bree,Pavlos Msaouel,Janet Baack Kukreja,Cheryl Mantaring,Innocent Rukundo, Martha Garcia Gonzalez,Justin R Gregg, Kelly N Casteel,Surena F Matin

The Journal of urology（2022）

引用 2|浏览18

暂无评分

摘要

There were fewer compliance events using apixaban for EP than enoxaparin after urologic oncology surgery. Regarding safety, apixaban is noninferior to enoxaparin and may in fact have fewer associated major complications.

查看译文

关键词

apixaban,factor Xa inhibitors,patient safety,postoperative complications,quality improvement

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要